How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation?

Human Pathology

Volumn 45, Issue 10, 2014, Pages 2029-2036

  Vilkin, Alex ^a   Halpern, Marisa ^b   Morgenstern, Sara ^a   Brazovski, Eli ^a   Gingold Belfer, Rachel ^a   Boltin, Doron ^a   Purim, Ofer ^a   Kundel, Yulia ^a   Welinsky, Sara ^a   Brenner, Baruch ^a,c   Niv, Yaron ^a,c   Levi, Zohar ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b HASHARON HOSPITAL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemoradiation; HNPCC; Immunohistochemical staining; Lynch; Neoadjuvant; Reliability

Indexed keywords

ANTINEOPLASTIC AGENT; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOSCOPIC BIOPSY; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECTUM CANCER; TUMOR BIOPSY; TUMOR DIFFERENTIATION; AGED; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; MIDDLE AGED; MISMATCH REPAIR; RADIATION RESPONSE; REPRODUCIBILITY; STANDARDS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; AGED; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84908217590     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.07.005     Document Type: Article

References (35)

1. H. Hampel, W.L. Frankel, and E. Martin Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) N Engl J Med 352 2005 1851 1860
2. H. Hampel, W.L. Frankel, and E. Martin Feasibility of screening for Lynch syndrome among patients with colorectal cancer J Clin Oncol 26 2008 5783 5788
3. H.F. Vasen, I. Blanco, and K. Aktan-Collan Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts Gut 62 2013 812 823
4. V. Pinol, A. Castells, and M. Andreu Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer JAMA 293 2005 1986 1994
5. R.C. Mercado, H. Hampel, and F. Kastrinos Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases Genet Med 14 2012 670 680
6. C.R. Boland, and M. Shike Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer Gastroenterology 138 2010 2197.e2191 2197.e2197
7. S.A. Byfield, and S. Syngal Clinical guidelines versus universal molecular testing: are we ready to choose an optimal strategy for Lynch syndrome identification? Am J Gastroenterol 103 2008 2837 2840
8. F. Kastrinos, E.W. Steyerberg, and J. Balmana Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer Gut 62 2013 272 279
9. L. Perez-Carbonell, C. Ruiz-Ponte, and C. Guarinos Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer Gut 61 2012 865 872
10. H. Hampel Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer J Natl Compr Canc Netw 8 2010 597 601
11. F. Kastrinos, E.W. Steyerberg, and R. Mercado The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history Gastroenterology 140 2011 73 81
12. U. Ladabaum, G. Wang, and J. Terdiman Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis Ann Intern Med 155 2011 69 79
13. L. Moreira, F. Balaguer, and N. Lindor Identification of Lynch syndrome among patients with colorectal cancer JAMA 308 2012 1555 1565
14. L.C. Beamer, M.L. Grant, and C.R. Espenschied Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results J Clin Oncol 30 2012 1058 1063
15. B. Heald, T. Plesec, and X. Liu Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center J Clin Oncol 31 2013 1336 1340
16. H.F. Vasen, I. Blanco, and K. Aktan-Collan Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts Gut 2013
17. E. Steinhagen, J. Shia, and A.J. Markowitz Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection J Am Coll Surg 214 2012 61 67
18. S.K. Warrier, A.H. Trainer, and A.C. Lynch Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy Dis Colon Rectum 54 2011 1480 1487
19. A.P. Kumarasinghe, B. de Boer, A.C. Bateman, and M.P. Kumarasinghe DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material Pathology 42 2010 414 420
20. J. Shia, Z. Stadler, and M.R. Weiser Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? Am J Surg Pathol 35 2011 447 454
21. N. Rahner, N. Friedrichs, and V. Steinke Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome J Pathol 214 2008 10 16
22. J. Shia, J.G. Guillem, and H.G. Moore Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome Am J Surg Pathol 28 2004 215 223
23. F. Bao, N.C. Panarelli, H. Rennert, D.L. Sherr, and R.K. Yantiss Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma Am J Surg Pathol 34 2010 1798 1804
24. O.M. Radu, M.N. Nikiforova, L.M. Farkas, and A.M. Krasinskas Challenging cases encountered in colorectal cancer screening for Lynch syndrome reveal novel findings: nucleolar MSH6 staining and impact of prior chemoradiation therapy Hum Pathol 42 2011 1247 1258
25. A.M. Bellizzi, C.D. Crowder, W.L. Marsh, H. Hampel, and W.L. Frankel Mismatch repair status in a cohort of rectal adenocarcinomas before and after chemoradiation Mod Pathol 23 2010 137A
26. F. Kastrinos, and S. Syngal Inherited colorectal cancer syndromes Cancer J 17 2011 405 415
27. J. Shia, L.H. Tang, and E. Vakiani Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel Am J Surg Pathol 33 2009 1639 1645
28. S. Olschwang, H. Blanche, C. de Moncuit, and G. Thomas Similar colorectal cancer risk in patients with monoallelic and biallelic mutations in the MYH gene identified in a population with adenomatous polyposis Genet Test 11 2007 315 320
29. E. Barrow, E. Jagger, and J. Brierley Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome Histopathology 56 2010 331 344
30. M. Guo, D. Klimstra, and L. Tang Immunohistochemistry (IHC) for DNA mismatch repair (MMR) proteins in colorectal carcinoma: what does scanty staining for MSH6 mean? Mod Pathol 23 Suppl 1 2010 433A
31. M.M. de las Alas, S. Aebi, and G. Los Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance J Natl Cancer Inst 89 1997 1537 1541
32. D. Fink, S. Nebel, and S.B. Howell The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells Br J Cancer 77 1998 703 708
33. F.L. Fonseca, A.V. Sant Ana, and I. Bendit Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients Breast Cancer Res 7 2005 R28 R32
34. C.L. Chang, G. Marra, and D.P. Chauhan Oxidative stress inactivates the human DNA mismatch repair system Am J Physiol Cell Physiol 283 2002 C148 C154
35. T. Oyama, Y. Ishikawa, M. Hayashi, K. Arihiro, and J. Horiguchi The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer Breast Cancer 14 2007 182 188